Date: 11 May, 2026
Location: Lausanne, Switzerland / Brussels, Belgium
The European Respiratory Society (ERS), a preeminent global authority in respiratory medicine, has officially announced that it is accepting applications for the prestigious and pivotal role of Chair of the Tobacco Control Committee. The appointment, which covers the 2026–2029 term, represents a critical juncture for public health advocacy in Europe as the continent faces evolving challenges regarding nicotine addiction, emerging tobacco products, and the ongoing struggle for a smoke-free generation.
Main Facts: The Role and the Mandate
The Tobacco Control Committee serves as the primary engine for the ERS’s strategic efforts in mitigating the health impact of tobacco and nicotine. Operating as a voluntary, unpaid position, the Chair acts as the primary representative for the society’s scientific and policy-oriented interests at the European Union (EU) level.
The successful candidate will inherit a robust portfolio of responsibilities, including the coordination of interdisciplinary teams, the oversight of advocacy campaigns, and the orchestration of the society’s response to legislative shifts in Brussels. The position is not merely administrative; it is a high-impact leadership role that requires an individual capable of bridging the gap between clinical research and political action.
Key Requirements for Applicants:
- Professional Standing: Applicants must possess a deep understanding of respiratory health and the public health ramifications of tobacco use.
- Membership: While all qualified individuals are invited to apply, the successful candidate must be a registered member of the ERS upon appointment.
- Commitment: The role entails a three-year term, requiring regular engagement with EU policy makers and ERS internal committees.
- Application Process: Candidates are invited to submit their comprehensive CVs and a formal letter of motivation via the official ERS recruitment portal by the deadline of 31 May 2026.
Chronology of ERS Tobacco Advocacy
To understand the weight of this role, one must examine the history of the ERS in the theater of tobacco control. Over the past two decades, the society has transitioned from a purely academic body to a powerful lobbyist for public health.
- Early 2010s: ERS intensified its focus on the Tobacco Products Directive (TPD), providing the scientific evidence base for stricter packaging requirements and the regulation of additives.
- 2018–2021: Under previous leadership, the committee spearheaded the "Tobacco-Free Europe" initiative, which aligned respiratory specialists with cancer researchers and cardiovascular experts to lobby for increased taxation on tobacco products.
- 2023–2026: Outgoing Chair Prof. Filippos Filippidis oversaw the expansion of the committee’s mandate to include the growing crisis of e-cigarettes and nicotine pouches among youth populations, signaling a shift toward addressing modern, non-combustible nicotine delivery systems.
- May 2026: The official call for the new Chair marks the beginning of the next cycle of advocacy, with a specific focus on the "Tobacco Endgame" targets set for 2040.
Supporting Data: The Landscape of Respiratory Health in Europe
The urgency of this role is underscored by the current statistics surrounding tobacco use in Europe. Despite significant gains in smoking cessation, the European Union still accounts for a disproportionate burden of smoking-related mortality.
The Epidemiological Burden
According to recent data from the European Respiratory Society and the World Health Organization (WHO) Europe, tobacco remains the single largest preventable cause of death in the region.
- Mortality: Approximately 700,000 deaths annually in the EU are attributed to tobacco-related diseases, including COPD, lung cancer, and cardiovascular incidents.
- The Cost of Inaction: The economic burden on European healthcare systems is estimated to be in the tens of billions of Euros annually, encompassing direct treatment costs and indirect losses in labor productivity.
- The Rise of Emerging Products: Data from 2025 indicates a 15% increase in the uptake of nicotine pouches among individuals aged 18–24, a trend that the incoming Chair will be expected to address with aggressive policy recommendations.
The Role of Policy in Clinical Outcomes
Clinical research confirms that medical intervention is only half the battle. Without legislative frameworks—such as the enforcement of smoke-free public spaces, restrictions on flavoring agents, and plain packaging—clinical cessation programs often fail to reach scale. The ERS Tobacco Control Committee is the primary body responsible for translating the "clinical truth" into "legislative language."
Official Responses and Reflections
The outgoing Chair, Prof. Filippos Filippidis, offered a candid reflection on the nature of the role, highlighting the unique intersection of science and politics.
"The Chair of the Tobacco Control Committee has amazing opportunities to interact with policy makers," Prof. Filippidis stated. "It is a role that demands more than medical expertise; it requires the ability to lead the development of influential ERS position papers that carry weight in the European Parliament. We are not just treating patients; we are working closely with the various branches of ERS to prevent nicotine addiction at the population level and promote evidence-based cessation. It is an exciting and profoundly meaningful role."
Leadership within the ERS emphasizes that the next Chair must be prepared for a highly politicized environment. The influence of the tobacco industry—and the emerging lobby for the "reduced risk" products—means that the Chair must be an expert in both data interpretation and strategic communication.
Implications for the Future of Public Health
The appointment of the new Chair will have far-reaching implications for the European healthcare landscape. As the EU continues to refine its "Europe’s Beating Cancer Plan," the ERS position on tobacco control will likely become the foundational standard for regional health directives.
Potential Policy Shifts (2026–2029)
- Harmonization of Taxation: The committee is expected to push for a more uniform approach to tobacco taxation across all 27 member states to prevent the "cross-border" consumption patterns that currently undermine national cessation efforts.
- Addressing Environmental Impact: There is a growing movement within the ERS to integrate environmental sustainability into tobacco control, focusing on the massive waste generated by single-use vape products and cigarette butts.
- Digital Health and Cessation: The next term will likely see a push for integrating digital health solutions, such as AI-driven cessation apps, into the standard care protocols endorsed by the ERS.
A Call for Diverse Leadership
The ERS has explicitly stated that all applications are welcome. The society is looking for a leader who can unify the diverse voices of respiratory clinicians, public health experts, and research scientists. The ideal candidate will be someone who can not only manage the committee’s internal affairs but also act as a public spokesperson, ready to challenge industry narratives with the objective, peer-reviewed science that the ERS is known for.
Conclusion
The search for the new ERS Tobacco Control Committee Chair is an invitation to take up the mantle of leadership at a critical time in European health policy. The role is challenging, requiring a high degree of commitment and political acumen, yet the impact is substantial. By providing the scientific guidance necessary to curb tobacco and nicotine consumption, the next Chair will play a direct role in shaping the health outcomes of millions of Europeans.
Interested candidates are reminded to review the full job description on the ERS website to understand the specific commitments and eligibility requirements. With the application window closing on 31 May 2026, the timeline for this transition is rapid. Those who wish to contribute to the future of respiratory health and the ongoing fight against the tobacco epidemic are encouraged to submit their materials promptly.
The ERS continues to stand as a beacon of clinical excellence and policy influence. The selection of the next Chair is not merely an internal staffing decision; it is a statement of intent for the future of public health in Europe.
